Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3qPxzqi
via IFTTT